The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Uttervall, Katarina ^a,b   Duru, Adil D ^a   Lund, Johan ^a,b   Liwing, Johan ^a   Gahrton, Gösta ^a   Holmberg, Erik ^c   Aschan, Johan ^d   Alici, Evren ^a,b   Nahi, Hareth ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d JanssenCilag AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; THALIDOMIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; DRUG USE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; SWEDEN; TREATMENT RESPONSE; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; REGISTER; RENAL INSUFFICIENCY; RETREATMENT; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; MORTALITY; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; REGISTRIES; RENAL INSUFFICIENCY; RETREATMENT; SWEDEN; TREATMENT OUTCOME;

EID: 84903897617     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101819     Document Type: Article

References (28)

1. Chanan-Khan AA, Giralt S (2010) Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 28: 2612-2624.
2. Dingli D, Pacheco JM, Nowakowski GS, Kumar SK, Dispenzieri A, et al. (2007) Relationship between depth of response and outcome in multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25: 4933-4937.
3. Alexanian R, Barlogie B, Dixon D (1990) Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Archives of internal medicine 150: 1693-1695.
4. Abbott KC, Agodoa LY (2001) Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clinical nephrology 56: 207-210.
5. Rayner HC, Haynes AP, Thompson JR, Russell N, Fletcher J (1991) Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single centre between 1975 and 1988. The Quarterly journal of medicine 79: 517-525.
6. Harousseau JL, Shaughnessy J Jr, Richardson P (2004) Multiple myeloma. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program: 237-256.
7. Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H (2008) Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22: 1485-1493.
8. Laubach J, Richardson P (2011) Hematology: Bortezomib and dexamethasone induction for multiple myeloma. Nature reviews Clinical oncology 8: 8-10.
9. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, et al. (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28: 4976-4984.
10. Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, et al. (2005) Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug metabolism and disposition: the biological fate of chemicals 33: 771-777.
11. Uttamsingh V, Lu C, Miwa G, Gan LS (2005) Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug metabolism and disposition: the biological fate of chemicals 33: 1723-1728.
12. Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, et al. (2006) Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108: 618-621.
13. Wu L, Adams M, Carter T, Chen R, Muller G, et al. (2008) Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 14: 4650-4657.
14. Chen N, Lau H, Kong L, Kumar G, Zeldis JB, et al. (2007) Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 47: 1466-1475.
15. Eriksson T, Höglund P, Turesson I, Waage A, Don BR, et al. (2003) Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J Pharm Pharmacol 55: 1701-1706.
16. Barlow L, Westergren K, Holmberg L, Talbäck M (2009) The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 48: 27-33.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of internal medicine 130: 461-470.
18. (2002) Part 4. Definition and classification of stages of chronic kidney disease. American journal of kidney diseases : the official journal of the National Kidney Foundation 39: S46-S75.
19. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, et al. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British journal of haematology 102: 1115-1123.
20. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, et al. (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 28: 4976-4984.
21. Ludwig H, Adam Z, Hajek R, Greil R, Tothova E, et al. (2010) Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin- dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 28: 4635-4641.
22. Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, et al. (2014) Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 25: 195-200.
23. Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, et al. (2013) The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia 27: 423-429.
24. Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, et al. (2009) VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 27: 6086-6093.
25. Roussou M, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, et al. (2010) Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 34: 1395-1397.
26. Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, et al. (2009) Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma 9: 302-306.
27. Eleftherakis-Papapiakovou E, Kastritis E, Roussou M, Gkotzamanidou M, Grapsa I, et al. (2011) Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. Leukemia & lymphoma 52: 2299-2303.
28. Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, et al. (2009) Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clinical lymphoma & myeloma 9: 302-306.